In 2026, theEFSA's provisional opinion on CBD clearly reshuffles the cards for the entire hemp sector in Europe. For market players, whether in ingredients, derivative products, textile innovation, or therapeutic access, the message is simple: value will no longer come solely from the plant, but from the ability to precisely document the quality, stability, process, and safety of the final product.
For adult consumers in France and Europe, this also changes how they view the market. Between CBD food supplements, processed extracts, hemp-derived textile fibers, and medical uses falling under a different regulatory framework, it becomes essential to distinguish between food, industrial, and therapeutic products. Here's what we can understand about the future of these sectors in light of recent EFSA positions and the regulatory changes expected in 2026.
EFSA's provisional opinion : a strong signal for CBD in food
In February 2026, the EFSA published a provisional safe intake level for CBD as a novel food: 0.0275 mg/kg of body weight per day. For a 70 kg adult, this represents approximately 2 mg of CBD per day. This threshold is particularly low compared to many commercial practices observed in recent years in the supplement market.
It is important to understand that this opinion is not a blanket endorsement of CBD in food. On the contrary, the Authority emphasizes persistent data gaps, particularly regarding the liver, but also the endocrine, nervous, and reproductive systems. In other words, the EFSA is not opening the floodgates; it is primarily reiterating that the safety assessment remains incomplete and subject to strict regulations.
For brands and supply chains, this point is crucial. It's no longer enough to simply say that a product is "made with hemp" or "contains CBD." The central question becomes the level of scientific evidence available on the specific ingredient, its manufacturing process, its purity, and its actual exposure to the user.
What this provisional dose actually covers
The provisional dose mentioned by the EFSA does not apply to all cannabidiol products. It applies only to food supplements with CBD that are at least 98% pure, free of nanoparticles, and produced using a process deemed safe. This distinction is crucial, as it effectively excludes many complex extracts or poorly characterized products.
The Authority also specifies that safety cannot be established for certain populations: those under 25, pregnant or breastfeeding women, and people undergoing medical treatment. This serves as a reminder that, when it comes to food use, caution depends not only on the dose, but also on the consumer's profile and potential interactions.
For the market, this means that a product that is compliant on paper must also be considered within its context of use. The future of derivative products therefore depends on clearer information, robust laboratory analyses, and responsible communication. This is a matter of compliance, but also of trust for informed buyers as well as for budget-conscious consumers who want to avoid vague promises.
Derivative products: the real battle is being fought over characterization
In March 2026, a scientific opinion from the EFSA on a Cannabis sativa extract obtained using CO₂ concluded that its safety could not be established under the proposed conditions of use. The dossier concerned food supplements with usage levels ranging from 1.12 mg/day to 3.60 mg/day depending on age, but this was not sufficient to convince the Authority.
Why this blockage? Because a substantial portion of the extract was not properly characterized, and toxicological and stability data on a representative sample were lacking. EFSA also reiterated that results from a different extraction process cannot be automatically extrapolated. This is a crucial point for all hemp and cannabis-derived products.
The more a derivative is processed, the higher the requirements become. Detailed composition, impurities, cannabinoid profiles, residual solvents, long-term stability, toxicology, and exposure assessment: everything must be robust. By 2026, the scientific message is consistent and unwavering. Moving upmarket requires evidence, not storytelling.
Revitalizing supply chains: from agricultural raw materials to high-value ingredients
For the industry, the economic stakes are considerable. Transforming an agricultural raw material into a higher value-added ingredient remains an attractive prospect, but it now depends less on the overall image of hemp than on the actual conformity of the final product. A prestigious plant origin is no substitute for a complete scientific dossier.
EFSA also points out that applications for CBD as a novel food remain numerous and that evaluation is carried out on a case-by-case basis. In its public materials, the Authority already indicated that in 2022 the European Commission had received more than 150 applications related to CBD as a novel food, with 19 dossiers then under evaluation. This volume demonstrates how competitive, but also selective, the sector is.
The sustainable recovery of these sectors will therefore depend on two very concrete levers: securing the supply chain and demonstrating the safety of the finished product. This implies higher industrial standards, independent analyses, proper traceability, and investments in technical documentation. For reputable operators, it is also an opportunity to clearly differentiate themselves.
Textiles: another avenue for valorization, outside the scope of EFSA
When discussing the revival of the hemp industry, textiles often come up as a promising avenue. However, it's important to be clear: this issue is primarily driven by industrial and environmental policies, not by the EFSA (European Food Safety Authority). The EFSA deals with the food safety of ingredients, not with textile strategy or fibers intended for clothing.
In France, the Senate announced that a bill aimed at reducing the environmental impact of the textile industry was definitively adopted on June 29, 2026. The legislation includes measures concerning consumer information and the promotion of ultra-fast fashion. This development could increase interest in more diverse, traceable, and potentially more valuable materials.
The same source also specifies that the text has been expanded to better inform consumers about the social impact of the products. For the hemp industry, this can support strategies of relocation, transparency, and differentiation around sustainable textiles. Here, the logic is not that of novel food, but rather that of environmental, social, and industrial regulation.
Therapeutic access: a framework distinct from dietary supplements
A fundamental point constantly resurfaces in the debates: food and medical uses do not fall under the same framework. The EFSA assesses the safety of ingredients intended for food, but it does not decide whether a substance is a medicine or a food supplement. This regulatory boundary is essential for understanding the future oftherapeutic access.
In France, the Ministry of Health published updated information in 2026 on early access authorization, compassionate access, and the compassionate prescribing framework. This means that potential therapeutic situations must be examined using specific medical logic and criteria, and not through the lens of novel drug designation.
At the European level, this momentum continues through the assessment of health technologies. The European Commission reiterates that Regulation (EU) 2021/2282 aims to improve the availability of innovative technologies, such as medicines and certain medical devices, for patients in the Union. For products derived from cannabis or hemp for therapeutic purposes, the path exists, but it requires the right regulatory framework.
Specific uses and medical responsibility
In French law, tissues, cells, and therapeutic products are also subject to specific regulations, including for certain off-specified uses when the recipient's health condition justifies it. Légifrance (the French legal database) specifies that distribution may be permitted if a practitioner certifies that the expected benefit outweighs the risk. This is a far cry from the logic of a wellness product sold online.
This distinction is important to avoid confusion in the public debate. A hemp-derived product may be of industrial interest, scientifically promising, or relevant in a very specific medical context, without automatically being admissible as a food or supplement. Each use has its own level of requirements and its own evidence-based process.
For professionals, this requires a clear strategy. Trying to do everything with a single extract is rarely realistic. Depending on the final use, a framework must be chosen, appropriate documentation created, and ambiguous promises avoided. It's a matter of compliance, but also of long-term credibility.
2026 and beyond: a more technical, but also more mature sector
Discussions on plant-derived products remain very active at EFSA in 2026. The Authority has notably announced a consultation on thebaine and oripavin in poppy seeds and derived products, scheduled for the third quarter of 2026. This shows that scientific vigilance does not only concern CBD, but more broadly processed plant ingredients.
EFSA has also strengthened its tools for accessing scientific information with a new catalogue of guidance documents. For those submitting industrial applications, this is a helpful signal: expectations are high, but the guidelines are becoming more accessible. Companies capable of seriously addressing compliance therefore have better resources to structure their development.
Ultimately, the message for 2026 is clear: the more a derivative product is processed, the higher the required proof of compliance. For the hemp, cannabis, and derived plant sectors, the future will not depend on fleeting trends, but on scientific rigor, industrial quality, and the ability to communicate effectively with both regulators and consumers.
TheEFSA's provisional opinion on CBD does not signal the end of opportunities; it primarily redefines the rules of the game. CBD products will have to prove much more, the textile industry will follow its own recovery path through environmental regulation, andtherapeutic access will continue to progress within a separate medical and institutional framework.
For both the supply chain and buyers, this new phase can be positive. A more demanding, better-documented, and more transparent market favors reputable players, lab-tested products, and responsible approaches. In short, the future remains open, but it will primarily belong to those who can translate the promise of hemp into concrete evidence of quality, compliance, and safety.
